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Abstract 37 
Background: Fractional exhaled nitric oxide (FeNO) is a safe and convenient test for assessing 38 
Th2 airway inflammation, which is potentially useful in the management of patients with chronic 39 
cough.  40 
Objective: To summarise the current evidence on the diagnostic usefulness of FeNO for predicting 41 
inhaled corticosteroid (ICS) responsiveness in patients with chronic cough 42 
Methods: A systematic literature review was conducted to identify articles published in peer-43 
reviewed journals up to February 2015, without language restriction. We included studies that 44 
reported the usefulness of FeNO (index test) for predicting ICS responsiveness (reference standard) 45 
in patients with chronic cough (target condition). The data were extracted to construct a 2 × 2 46 
accuracy table. Study quality was assessed with QUADAS-2. 47 
Results: We identified five original studies (two prospective and three retrospective studies). We 48 
identified considerable heterogeneities in study design and outcome definitions, and thus were 49 
unable to perform a meta-analysis. The proportion of ICS responders ranged from 44% to 59%. 50 
Sensitivity and specificity ranged from 53% to 90%, and from 63% to 97%, respectively. The 51 
reported area under the curve (AUC) ranged from about 0.60 to 0.87; however, studies with a 52 
prospective design and a lower prevalence of asthma had lower AUC values. None measured 53 
placebo effects or objective cough frequency.  54 
Conclusions: We did not find strong evidence to support the use of FeNO tests for predicting ICS 55 
responsiveness in chronic cough. Further studies need to have a randomised, placebo-controlled 56 
design, and should use validated measurement tools for cough. Standardisation would facilitate 57 
the development of clinical evidence. 58 
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Word count: 250 60 
 61 
Highlight box 62 
1. What is already known about this topic? 
Th2 inflammation in the airways is a major factor contributing to cough hypersensitivity. 
Fractional exhaled nitric oxide (FeNO) is a safe and convenient test to measure the degree of 
Th2 inflammation in the airways.  
 
2. What does this article add to our knowledge? 
Current findings on the diagnostic usefulness of FeNO in predicting inhaled corticosteroid 
responsiveness (ICS) in chronic cough patients are conflicting.   
 
3. How does this study impact current management guidelines? 
Further well-designed prospective placebo-controlled studies with validated outcome 
measurement tools and standardized protocols are warranted to recommend the use of FeNO 
tests in predicting ICS responsiveness in clinical guideline of chronic cough.  
 63 
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Abbreviations 67 
ICS, inhaled corticosteroid 68 
FeNO, fractional exhaled nitric oxide 69 
eNO, exhaled nitric oxide 70 
IL, interleukin 71 
AUC, area under the curve 72 
ROC, receiver operating characteristic 73 
QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies 2 74 
SROC, summary receiver operating characteristic 75 
LCQ, Leicester Cough Questionnaire 76 
VAS, visual analogue scale 77 
BHR, bronchial hyper-responsiveness 78 
FEV1, forced expiratory volume in 1 second 79 
FVC, forced vital capacity 80 
RTI, respiratory tract infection 81 
SD, standard deviation 82 
IQR, interquartile range 83 
SE, standard error 84 
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95% CI, 95% confidence interval 85 
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Introduction 87 
Chronic cough is a common clinical condition arising from hypersensitivity of cough reflex 88 
pathways.1, 2 Among several peripheral triggers of cough reflex pathways, airway eosinophilic 89 
inflammation is one of the most well-known with respect to the mechanism of action and clinical 90 
implications. Th2 inflammatory mediators induced in conditions like asthma or eosinophilic 91 
bronchitis can directly activate or sensitise airway sensory nerves, leading to cough 92 
hypersensitivity.3 Importantly, this type of airway inflammation responds well to inhaled 93 
corticosteroid (ICS) therapy.2 Thus, it is of clinical relevance to identify ‘ICS-responsive cough’ 94 
at the early stage of diagnosis.4  95 
Traditionally, induced sputum analysis has been utilised to guide decisions for ICS treatment 96 
initiation. Airway eosinophilic inflammation (usually defined by an induced sputum eosinophil 97 
count ≥ 2-3%), even in the absence of asthma, has been recognised to show good responsiveness 98 
to ICS.5, 6 However, induced sputum analysis is technically demanding with respect to the 99 
standardisation of induction, processing, and interpretation procedures; thus, its use has mostly 100 
been restricted to specialised centres and the validation of more convenient alternative markers are 101 
warranted.7  102 
The fractional exhaled nitric oxide (FeNO) test is a recently developed inflammometer to detect 103 
Th2 inflammation in the airways. The main origin of exhaled nitric oxide (eNO) is the respiratory 104 
epithelium. Inducible NO synthase, the enzyme that produces NO, is mostly upregulated by 105 
interleukin (IL)-4 and IL-13.8 Thus, FeNO levels may reflect the degree of Th2-type airway 106 
inflammation, and the test is considered as a safe and convenient alternative to induced sputum 107 
analysis or the methacholine challenge test.9  108 
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In asthma, FeNO levels showed a good correlation with induced sputum eosinophilia in a recent 109 
meta-analysis7, and FeNO has also been considered as a good clinical predictor of ICS 110 
responsiveness, particularly in terms of reducing exacerbation.10 In chronic cough, FeNO level 111 
was reported to be a good predictor of cough variant asthma or eosinophilic bronchitis among 112 
chronic cough patients.11, 12 Moreover, the FeNO level was suggested to be more useful in 113 
predicting ICS responsiveness than any other markers, such as the induced sputum eosinophil 114 
count, among chronic persistent cough patients.13 Thus, we hypothesised that the FeNO test would 115 
be useful in predicting ‘ICS responsiveness’ in unselected chronic cough patients. In the literature 116 
so far, this research question has not been systematically reviewed. Here, we conducted a 117 
systematic review to summarise the current evidence on the diagnostic usefulness of the FeNO test 118 
in predicting ICS responsiveness in chronic cough patients.  119 
 120 
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Methods 122 
Literature search 123 
We searched the PubMed, Embase, Web of Science and Scopus databases according to the 124 
recommendation of the PRISMA statement.14 The search terms used were “cough” AND “nitric 125 
oxide” for articles published in peer-reviewed journals up to February 2015, without language 126 
restriction. Additional searches of Google Scholar and clinical trial registries (clinicaltrials.gov 127 
and isrctn.com) were performed. If full-text links were not available, we contacted the 128 
corresponding authors by electronic mail. We included studies if they had reported the usefulness 129 
of FeNO (set as an index test) for predicting ICS responsiveness (as a dichotomous outcome; set 130 
as the reference standard) in patients with chronic cough (set as the target condition). Any 131 
dichotomous criterion for determining ICS treatment responsiveness was accepted if it was 132 
specified within the manuscript. Studies were excluded if they were not original papers (review 133 
articles or case reports) or did not determine ICS responsiveness as a dichotomous outcome. Two 134 
independent authors screened the titles and abstracts of all of the search results and determined the 135 
eligibility of each study. Any discrepancy in the selection was resolved by consensus between the 136 
authors.  137 
Data extraction and quality assessment  138 
For all of the included articles, data were extracted pertaining to the first author, journal, 139 
publication year, country, study design, clinical setting, sample size, characteristics of the study 140 
participants (age, sex, corticosteroid treatment history, and asthma prevalence), and ICS treatment 141 
and responsiveness (%). Additionally, we extracted the results of index tests, the reference standard, 142 
test positivity thresholds, area under the curve (AUC) values, and data for constructing 2 × 2 tables 143 
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giving the index test results by reference standard results for each reported threshold. If 2 × 2 tables 144 
were not reported in the original papers, we reconstructed them from summary estimates or from 145 
the electronic mail contacts of the corresponding authors. In any case of an included study that did 146 
not report the optimal cut-off value of the index test (FeNO), we performed receiver operating 147 
characteristic (ROC) curve analysis using the original data provided by the corresponding authors 148 
and also determined the optimal cut-off value using the Youden index (sensitivity + specificity – 149 
1). Two independent authors assessed the risk of bias, as well as applicability concerns, using the 150 
Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.15  151 
Statistical analysis 152 
From each constructed 2 × 2 table, we calculated estimates of the sensitivity and specificity, as 153 
well as 95% confidence intervals. The extracted data were summarised as a forest plot. 154 
Additionally, because the sensitivity and specificity change according to the threshold level, 155 
summary ROC (SROC) curves were also generated.16 Heterogeneity was defined as significant if 156 
I2 > 50%. We used Egger’s test to assess the risk of publication bias. All of the statistical analyses 157 
were performed using RevMan software (ver. 5.3; Cochrane Collaboration, Oxford, UK) and the 158 
meta-analysis modules of Stata (ver. 14.1; Stata Corp., College Station, TX, USA) (metan, 159 
metabias and metandi). 160 
161 
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Results 162 
Characteristics of included studies 163 
Among 916 initially retrieved abstracts, five original articles finally met the inclusion criteria 164 
(Figure 1).17-21 Chaudhuri et al.13 the first report on this topic, was excluded because 165 
responsiveness to treatment was not reported as a dichotomous outcome and the sensitivity and 166 
specificity data could not be retrieved after contacting the corresponding author. Zhang et al.,22 167 
which examined the usefulness of FeNO tests for ICS responsiveness was excluded at the final 168 
selection stage because ICS was selectively administered to a subgroup of patients with cough-169 
variant asthma or eosinophilic bronchitis, but not to an unselected group of cough patients 170 
(Appendix Table 1). No discrepancy existed in the selection of articles among the co-authors. 171 
The detailed characteristics of the five included studies are summarised in Table 1. For the study 172 
of Watanabe et al.21, we extracted the datasets of all of the patients (n = 77) and the ICS-naïve 173 
patients (n = 34) separately. Across all of the studies, the number of participants ranged from 34 to 174 
77. The mean age ranged from 47 to 56 years, and female gender was more frequent in all of the 175 
studies (from 51% to 74%); these findings are in line with the usual demographic findings of 176 
patients visiting cough clinics.23 None of the studies included children. Four studies were based on 177 
referral clinics17-19, 21; however, one prospective study recruited participants via newspaper 178 
advertisements.20 The definition of chronic cough was > 8 weeks in most of the studies17-20 but 179 
was > 3 weeks in one Japanese study.21 The median duration of cough before the study ranged 180 
from 12 months to 8.5 years.  181 
Normal chest radiographs and not currently smoking were common criteria for selection (Table 2). 182 
All of included studies examined unselected patients presenting with chronic cough. All the 183 
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participants did not receive any specific diagnosis for cough before the studies. Major trigger 184 
conditions such as eosinophilic bronchitis, upper airway cough syndrome, or gastroesophageal 185 
reflux were not excluded. Previous history of doctor-diagnosed asthma was an exclusion criterion 186 
in one study; however, the results showed that 21% of study participants still had asthma and 50% 187 
of them showed mild responsiveness to histamine.20 History of corticosteroid exposure was 188 
checked in all studies. Two studies had subgroups of ICS-naïve patients.17, 21 In Hsu et al., ICS was 189 
not administered until at least 1–2 weeks before FeNO measurement, according to their stepwise 190 
protocol.19 In Koskela et al., all subjects were naïve to inhaled or systemic corticosteroid therapy 191 
(personal communication with the corresponding author).20 192 
The study characteristics related to the ICS treatment protocol and outcomes are summarised in 193 
Table 3. The dose and duration of ICS treatment were pre-specified in three studies18-20, but were 194 
not specified in two retrospective studies.17, 21 In these latter two studies, the ICS dose/duration 195 
was about 435 µg/day fluticasone for a median period of 5–6 months17, or the usual dose ICS for 196 
≥ 3 months21, respectively. The criteria for ICS treatment responsiveness was heterogeneous; one 197 
prospective trial defined responsiveness by a reduction > 50% in the mean daily cough symptom 198 
score18, and another prospective trial determined responsiveness by a ≥ 1.3-point improvement in 199 
the Leicester Cough Questionnaire (LCQ) score (corresponding to a minimally important 200 
change).20 Three retrospective studies defined the outcome as ‘significant improvement’ or 201 
‘complete control of cough (determined by physician)’.17, 19, 21  202 
Quality assessment 203 
The detailed results of the QUADAS-2 assessment are provided in Figure 2. Two prospective 204 
studies had an unclear risk of bias in one domain (reference standard).18, 20 Three retrospective 205 
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studies were determined to be at risk of bias in several domains17, 19, 21; in particular, we determined 206 
that they had a risk of bias during the process of participant recruitment (Table 1) or the decision 207 
to prescribe ICS (Table 3). In the domain of participant selection, the studies without random or 208 
consecutive recruitment (or without specific criteria for ICS prescription) were classified as having 209 
an unclear risk of bias. 210 
In the domain of reference standard (ICS responsiveness), three retrospective studies used rather 211 
arbitrary criteria (significant improvement or complete control) and were classified as having an 212 
unclear or high risk of bias17, 19, 21; in a retrospective study, the decision of whether to administer 213 
ICS was partly based on the FeNO level; thus, the study was classified as having a high risk of 214 
bias.19 Two prospective studies utilised a structured questionnaire (LCQ or daily cough symptom 215 
score) but did not include a placebo in determining ICS responsiveness, and thus were classified 216 
as having an unclear risk of bias.18, 20 None of these included studies measured objective cough 217 
frequency. 218 
Exclusion rates among retrospective studies were higher than 20% in two studies17, 19, which were 219 
determined to have an unclear risk of bias in the domain of flow and timing. No risks of bias, and 220 
no concerns regarding applicability, were noted in conducting and interpreting the index test 221 
(FeNO measurement) because the test utilised standardised commercial instruments.  222 
Usefulness of FeNO for predicting ICS responsiveness 223 
The proportion of ICS responders ranged from 44% to 59% (Table 2). A 2 × 2 table was constructed 224 
to summarise the diagnostic usefulness of FeNO tests. The sensitivity and specificity ranged from 225 
53% to 90% and from 63% to 97%, respectively. The optimal cut-off values also varied, from 16.3 226 
to 38 ppb. Two prospective studies had lower values in terms of Youden indices relative to three 227 
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retrospective studies (0.1618, 0.3620 vs. 0.5921, 0.7119, and 0.7417). The AUC ranged from 0.74 to 228 
0.87; one prospective study did not report the AUC value but apparently had a low AUC value, 229 
close to 0.60 (based on the ROC curve figure in the original paper).18 The SROC curve is presented 230 
in Figure 4, with additional subgroup representation by study design (prospective study vs. 231 
retrospective study). The retrospective studies had a higher diagnostic usefulness with respect to 232 
the FeNO level and a higher proportion of asthma sufferers (ranging from 19.7% to 48.4%; Table 233 
1). There was no significant risk of publication bias (p=0.448). I2 value was 76.4%. We decided 234 
not to perform meta-analyses because there was considerable heterogeneity among the study 235 
designs and outcome measurements.  236 
237 
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Discussion 238 
In the present systematic review, we did not find sufficient evidence to advocate the use of FeNO 239 
measurement for predicting ICS responsiveness among unselected chronic cough patients. First, 240 
due to considerable heterogeneities in the study protocols and outcome definitions, we could not 241 
perform pooled analyses. Second, mixed results were identified with methodological concerns; the 242 
studies with a relatively lower risk of bias and prospective design reported a lower diagnostic 243 
usefulness of the FeNO test, whereas those reporting a high diagnostic usefulness of FeNO tests 244 
had retrospective designs and included a higher proportion of asthma patients. However, none of 245 
the included studies measured placebo effects. Collectively, these results warrant further 246 
prospective placebo-controlled trials using standardised protocols and validated measurement 247 
tools. 248 
The study of Chaudhuri et al. was the first investigation of the effects of ICS on the FeNO levels 249 
among an unselected sample of 88 patients with chronic persistent cough (consisting of 30 250 
postnasal drip cough syndrome, 18 gastroesophageal reflux, 13 cough variant asthma, 9 251 
bronchiectasis and 10 idiopathic cough patients).13 In their double-blind, randomised, placebo-252 
controlled study, treatment with inhaled fluticasone 500 mcg twice daily for 14 days resulted in a 253 
mean improvement of 22.3% in cough visual analogue scale (VAS) score. Notably, the 254 
improvement in the cough VAS score was more strongly correlated with baseline FeNO level (r2 255 
= 0.151, p<0.001) than with sputum eosinophil (r2 = 0.08, p=0.019) or sputum eosinophil cationic 256 
protein level (r2 = 0.064, p=0.05). These results led to positive speculation on the usefulness of 257 
FeNO tests in predicting ICS responsiveness. 258 
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In contrast to the previous positive expectation, however, we found that the discriminating power 259 
of the FeNO test for ICS responsiveness remains questionable. The prospective study of Prieto et 260 
al.18, which had a relatively lower risk of bias, demonstrated that FeNO tests did not appear to have 261 
sufficient power to discriminate between ICS-responsive and -unresponsive cough (sensitivity, 262 
53%; specificity, 63% [at a cut-off of 20 ppb]). The question arises as to whether the treatment 263 
dose or duration was insufficient (fluticasone propionate 100 mcg twice daily for 4 weeks); 264 
however, the response to ICS therapy in eosinophilic bronchitis is known to be very rapid; i.e. 265 
within 1 or 2 weeks of treatment initiation.5, 6 Moreover, the positive response rate (defined as a 266 
reduction of > 50% in the mean daily cough symptom score) was 44%, which was comparable to 267 
other studies.17-19, 21 Another prospective study with a relatively lower risk of bias, by Koskela et 268 
al.20, also reported fair but less than expected diagnostic usefulness of the FeNO test (AUC, 0.74; 269 
sensitivity, 47%; specificity, 89% [at a cut-off of 16.3 ppb]). The positive response rate to 270 
budesonide 400 mcg, twice daily for 12 weeks, was as high as 77% (defined as an improvement 271 
in the LCQ score > 1.3 [minimally important change]).  272 
The results from two prospective studies might collectively suggest that FeNO tests do not 273 
sufficiently differentiate ICS-responsive from ICS-unresponsive cough in unselected patients with 274 
chronic cough. However, neither study tested for placebo effects,18, 20 and the possibility of 275 
spontaneous cough remission could not be fully excluded. Spontaneous recovery might be a reason 276 
for high ICS responder rates (44–77%) observed in two prospective studies with low baseline 277 
FeNO levels.18, 20 Placebo-controlled studies demonstrated that FeNO is a very good predictor of 278 
ICS treatment responses in patients with asthma or undiagnosed respiratory symptoms.24, 25 279 
Therefore, placebo-controlled trials are required to confirm the diagnostic utility of FeNO for 280 
predicting ICS responsiveness in patients with chronic cough.  281 
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Due to the relatively higher risk of bias, the results from the three included retrospective studies 282 
may need to be carefully interpreted (AUC 0.85-0.87).17, 19, 21 Above all, the criterion to initiate 283 
ICS treatment and determine the treatment responsiveness was not prospectively specified by the 284 
studies, but was instead determined subjectively; furthermore, it was not clearly stated whether the 285 
study participant selection criteria were pre-specified.  286 
Another consideration is that these three retrospective studies included higher proportions of 287 
patients with asthma or bronchial hyperresponsiveness (BHR) (48.4%, 21.1% and 35.3%, 288 
respectively17, 19, 21) than did the two prospective studies (9% and 21%, respectively).18, 20 When 289 
eosinophilic bronchitis was included, the prevalence of asthma syndrome (asthma or non-290 
asthmatic eosinophilic bronchitis), which is considered to be ICS-responsive cough2, increased to 291 
53.1–56.6% in these retrospective studies.17, 19 Within the subgroup of cough-variant asthma or 292 
eosinophilic bronchitis, the changes in FeNO levels were reported to correlate well with the 293 
improvement in cough symptom scores after ICS treatment (n = 48; r = 0.48, p = 0.004).22 In a 294 
placebo-controlled study involving 52 patients with undiagnosed respiratory symptoms, ICS 295 
treatment effects were clearly shown in a subgroup with high FeNO levels (> 47 ppb) but not in 296 
subgroups with lower FeNO levels (<15 or 15–47 ppb).24 Collectively, these findings could 297 
indicate improved predictive usefulness of FeNO tests in clinical settings characterised by a high 298 
proportion of asthma syndrome sufferers, or high baseline FeNO levels among chronic cough 299 
patients, such as primary or early referral clinics, or in Asian regions.26, 27 The comparison of the 300 
five studies included in our systematic review also suggested such potential (Figure 4). This 301 
speculation warrants a prospective investigation under these particular conditions, which could 302 
achieve a high diagnostic yield. 303 
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The utility of FeNO for differentiating ICS responsiveness in non-asthmatic and non-eosinophilic 304 
cough patients remains to be clarified; such trials have not been published to our knowledge. Non-305 
asthmatic and non-eosinophilic patients are less likely to have Th2 inflammation and FeNO 306 
elevation.28 Prieto et al.18 and Koskela et al.20, in which study participants had near-normal FeNO 307 
levels, suggested poor predictive value of FeNO in clinical settings with low FeNO. However, as 308 
discussed earlier, placebo-controlled trials are necessary to confirm the diagnostic utility. 309 
Reports of diagnostic test accuracy are often based on routinely collected clinical data rather than 310 
prospectively registered trials,29 and studies with a retrospective design are not excluded in 311 
systematic reviews of diagnostic utility of nitric oxide in different diseases.7, 30 However, 312 
considering the significance of placebo effects in the therapeutic evaluation of cough patients,31 313 
further investigations on this topic should have a randomised, placebo-controlled design. In 314 
addition, a cross-over design should be avoided due to possible carry-over effects of ICS 315 
treatment.32 Participants need to be consecutively or randomly recruited, as a case-control 316 
comparison study could overestimate diagnostic usefulness.29 Several parameters also need to be 317 
assessed at baseline, such as atopy, smoking, BHR, sputum eosinophil counts, and previous history 318 
of corticosteroid treatment, as they could influence FeNO levels8 and thus enable subgroup 319 
analyses.  320 
There is still no consensus on the dosage and duration of ICS for this research topic. The Cochrane 321 
review suggested that high-dose ICS for 2 weeks is an appropriate option32, but longer treatment 322 
duration could be helpful in patients with longstanding cough. It would be ideal if a consensus on 323 
the research protocol is made to guide further clinical trials on treatment responsiveness of cough 324 
in patients with chronic cough, or other respiratory conditions. Finally, as the outcomes for cough 325 
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responsiveness, the use of validated questionnaires such as the LCQ33 and Cough Quality of Life 326 
Questionnaire34 are recommended.35 Combination with objective cough frequency measurement 327 
is also recommended, as it has the potential to reflect different aspects of cough.35, 36 328 
Standardisation would help to collect clinical evidence and draw specific recommendations on the 329 
use of FeNO as guidance for ICS therapy in further clinical guidelines. 330 
Choice of empirical treatment in cough patients without initial indicators for specific cough may 331 
differ by population or clinical settings. First-generation anti-histamine/decongestant or ICS 332 
therapy has been recommended in current guidelines by the American College of Chest 333 
Physicians37, or the European Respiratory Society38 respectively. Thus, the ideal position of FeNO 334 
measurement, as a guidance for ICS therapy, in the clinical pathway of chronic cough is still not 335 
determined. Considering that the benefits of ICS therapy and FeNO test may depend on the patient 336 
characteristics or clinical settings, further clinical trials evaluating FeNO need to be tailored for 337 
expected target population. 338 
In conclusion, we did not find strong evidence to support the use of FeNO tests to predict ICS 339 
responsiveness in unselected patients with chronic cough. Only a few studies were identified, but 340 
they had mixed results with methodological heterogeneities and concerns. Future studies should 341 
have a randomised, placebo-controlled design and use validated measurement tools for cough.  342 
 343 
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Table 1. Baseline characteristics of five original papers that reported the usefulness of fractional exhaled nitric oxide tests for predicting inhaled corticosteroid treatment 
response among patients with chronic cough 
Studyref Design n Age 
(yr) 
Female 
(%) 
Location Definition of 
chronic cough 
Recruitment  FeNO 
measurement 
Median cough 
duration 
Cough variant 
asthma (%)* 
Hahn 
200717 
Retrospective 64 47 59.4% USA Cough ≥8 
weeks  
Selected from 
clinical database 
of 114 patients 
referred to 
specialist clinics 
for evaluation of 
chronic cough 
Sievers Model 
280i (Sievers, 
Boulder, CO, 
USA) 
41 months 48.4%a 
Prieto 
200918 
Prospective, 
open-label 
43 48 58.1% Spain Cough ≥8 
weeks 
 
Consecutively 
recruited from 
patients referred 
to specialist 
clinics 
NIOX 
(Aerocrine; 
Solna, Sweden) 
ND 9%a 
Hsu 201319 Retrospective 81 49 59.3% Taiwan Cough ≥8 
weeks  
Selected from 
medical record of 
Sievers Model 
280i (Sievers, 
12 months 21.1%a 
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114 patients who 
visited specialist 
clinics 
Boulder, CO, 
USA) 
Koskela 
201320 
Prospective, 
open-label 
43 55.6 74% Finland Cough ≥8 
weeks  
Consecutively 
recruited via 
newspaper 
advertisement 
Sievers Model 
280 (Sievers, 
Boulder, CO, 
USA) 
8.5 years 21%b 
Watanabe 
201421 
Retrospective 77 50.5 59.5% Japan Cough ≥3 
weeks  
Selected from 
clinical records of 
86 adult patients 
referred to a 
university 
hospital for 
persistent cough 
NIOX MINO 
(Aerocrine; 
Solna, Sweden) 
16.8 months 50.6%c  
Watanabe 
2014 
(steroid 
naïve 
Retrospective 34 44.6 51.4% Japan Cough ≥3 
weeks  
Selected from 
clinical records of 
86 adult patients 
referred to a 
NIOX MINO 
(Aerocrine; 
Solna, Sweden) 
13.7 months 35.3%c 
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sample)21 university 
hospital for 
persistent cough 
Abbreviations: FeNO, fractional exhaled nitric oxide; ND, not described 
*Asthma was defined by (a) methacholine challenge tests, (b) questionnaire, or (c) clinical diagnosis by specialist. 
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Table 2. Summary of the selection criteria for participants in included studies 
Studyref Age  Chest X-ray Lung function  Smoking 
history 
Medication 
history 
History of other 
lung diseases 
History of 
respiratory tract 
infection 
Other  
Hahn 200717 ≥18 years  Normal ND No current 
smoker 
No current ACE 
inhibitor use 
ND ND  
Prieto 200918 18-70 years  Normal FEV1≥80% 
predicted 
Non-smoker No current ACE 
inhibitor or β-
blockers use 
No previous 
history of 
corticosteroid 
use 
No other lung 
diseases on the basis 
of history, clinical 
examination, and 
computed 
tomography scan if 
necessary 
No RTI within 4 
weeks 
 
Hsu 201319 ND Normal ND No current 
smoker 
No previous 
smoking 
history >10 
pack-year 
ND ND ND  
Koskela 201320 ND Normal ND No current 
smoker 
ND No previous history 
of doctor diagnosed 
asthma  
No febrile RTI 
within 6 weeks 
 
Watanabe 
201421 
≥15 years  Normal ND No current 
smoker 
(subgroup) 
Inhaled 
corticosteroid 
naïve 
(subgroup) 
ND ND Normal 
pulmonary 
auscultation 
Abbreviations: FEV1, forced expiratory volume in 1 second; RTI, respiratory tract infection; ND, not described.
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Table 3. Characteristics related to inhaled corticosteroid treatment responsiveness 
Studyref Criteria for 
prescribing ICS 
ICS dose and 
duration 
Definition of ICS 
responsiveness 
ICS responder (%) Baseline FeNO levels 
among responder 
(ppb) 
Baseline FeNO levels 
among non-responder 
(ppb) 
Hahn 200717 Clinical judgement 
(specific criteria was 
not described) 
Mean FP 419-445 
mcg/day for median 
5-6 months 
All of the following 
criteria: (1) 
physician-
documented 
significant 
improvement in 
cough, (2) no further 
diagnostic studies 
ordered for 
assessment of cough, 
and (3) no alteration 
in ICS dose 
59% Mean 51.25 ± SD 20.1 
ppb 
Mean 26.0 ± SD 16.5 
ppb 
Prieto 200918 Prescribed to all 
participants by study 
FP 100 mcg bid for 4 
weeks 
Reduction of >50% 
in mean daily cough 
44% Geometric mean 23.2 
(95% CI 17.5-30.7) 
Geometric mean 18.6 
(95% CI 14.7-24.0) 
 ©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
26 
 
protocol symptom score 
Hsu 201319 Clinical judgement 
(prescribed when 
cough persisted after 
initial symptomatic 
treatment and if 
FeNO level was ≥30 
ppb, if there was 
borderline to positive 
BHR, or if baseline 
FEV1%/FVC<70%) 
FP 250 mcg bid for > 
2 weeks 
Complete control of 
cough (determined 
by physician) 
50% NA NA 
Koskela 201320 Prescribed to all 
participants by study 
protocol 
Budesonide 400 mcg 
bid for 12 weeks 
Improvement in 
Leicester Cough 
Questionnaire score 
≥ 1.3 points (minimal 
important change) 
77% Mean 19.7 (median 
15.7, IQR 9.2-22.1) 
Mean 9.8 (median 9.6, 
IQR 5.5-13.2) 
Watanabe 201421 Clinical judgement 
(decided 
Practical dose of ICS 
for ≥ 3 months 
Significant 
improvement in 
54.5% Mean 54.5 ± SE 7.1 
ppb 
Mean 21.1 ± SE 1.6 
ppb 
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comprehensively 
with history or data 
of patients by 
physicians) 
 cough with ICS for 
more than 3 months 
(declared by the 
patients and 
confirmed by 
physician) 
Watanabe 201421 
(steroid naïve 
sample) 
Clinical judgement 
(decided 
comprehensively 
with history or data 
of patients by 
physicians) 
Practical dose of ICS 
for ≥ 3 months 
 
Significant 
improvement in 
cough with ICS for 
more than 3 months 
(declared by the 
patients and 
confirmed by 
physician) 
41% Mean 60.6 ± SE 14.1 
ppb 
Mean 22.2 ± SE 2.3 
ppb 
Abbreviations: ICS, inhaled corticosteroid; FeNO, fractional exhaled nitric oxide; FP, fluticasone propionate; SD, standard deviation; 95% CI, 95% confidence interval; 
BHR, bronchial airway hyper-responsiveness; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; IQR, interquartile range; SE, standard error 
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Figure 1. PRISMA for study selection 
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Figure 2. QUADAS-2 quality assessment of the included studies. (A) Graph showing the risk 
of bias and concerns regarding applicability: review of authors' judgements in each domain, 
presented as percentages across the included studies. (B) Risk of bias and concerns regarding 
applicability summary: review of authors' judgements in each domain for all included studies. 
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Figure 3. Forest plot summarising the findings of each study regarding the usefulness of 
fractional exhaled nitric oxide (FeNO) tests for predicting inhaled corticosteroid (ICS) response 
in chronic cough patients. The study of Watanabe 2014 indicates the results from steroid-naïve 
samples. 
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Figure 4. Summary receiver operating characteristics curve for FeNO tests with respect to 
prediction of ICS responsiveness among patients with chronic cough, subgrouped by study 
design. The study of Watanabe 2014 indicates the results from steroid-naïve samples. 
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